Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen-Reference-Cited by-同舟云学术

Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen

Published:2020-11-30 Issue:2 Volume:96 Page:234-240
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Chiusolo Patrizia¹²^ORCID,Bregante Stefania³,Giammarco Sabrina¹,Lamparelli Teresa³,Casarino Lucia⁴,Dominietto Alida³,Raiola Anna Maria³,Metafuni Elisabetta²^ORCID,Di Grazia Carmen³,Gualandi Francesca³,Sora Federica¹²^ORCID,Laurenti Luca¹²^ORCID,Sica Simona¹²,Barosi Gianni⁵,Guolo Fabio⁶^ORCID,Rossi Monica²,Rossi Elena¹²,Vannucchi Alessandro⁷,Signori Alessio⁸,De Stefano Valerio¹²^ORCID,Bacigalupo Andrea¹²,Angelucci Emanuele³

Affiliation:

1. Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia Fondazione Policlinico Universitario A. Gemelli IRCCS Rome Italy

2. Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche Università Cattolica del Sacro Cuore Rome Italy

3. UO Ematologia e Trapianto di Midollo Osseo, IRCCS Ospedale Policlinico San Martino Genova Genova Italy

4. Istituto di Medicina Legale, Universita’ di Genova Genova Italy

5. Centro per lo Studio della Mielofibrosi, IRCCS Policlinico San Matteo Pavia Italy

6. Istituto di Ematologia, Universita’ di Genova Genova Italy

7. CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Universita’ di Firenze, AOU Careggi Florence Italy

8. Sezione di Biostatistica, Dipartimento di Scienze della Salute, Universita’ di Genova Genova Italy

Funder

Associazione Italiana per la Ricerca sul Cancro

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26042

Reference19 articles.

1. Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups

2. Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT)

3. CD34 Selected Cells for the Treatment of Poor Graft Function after Allogeneic Stem Cell Transplantation

4. Treatment of poor graft function after allogeneic hematopoietic cell transplantation with a booster of CD34-selected cells infused without conditioning

5. CD34+-Selected Stem Cell Boost without Further Conditioning for Poor Graft Function after Allogeneic Stem Cell Transplantation in Patients with Hematological Malignancies

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Azacitidine combined with interferon‐α for pre‐emptive treatment of AML/MDS after allogeneic peripheral blood stem cell transplantation: A prospective phase II study;British Journal of Haematology;2024-07-03

2. Strategies to reduce relapse risk in patients undergoing allogeneic stem cell transplantation for acute myeloid leukaemia;British Journal of Haematology;2024-04-11

3. Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT;Bone Marrow Transplantation;2024-03-15

4. 2024 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management;American Journal of Hematology;2024-03-07

5. Laboratory methods of monitoring disease response after allogeneic haematopoietic stem cell transplantation for myelofibrosis;Pathology;2024-02